In summary, postmenopausal carriers of PVs in BRCA1/2, ATM, CHEK2, and PALB2 are unlikely to have substantial (twofold or greater) elevations in the risk of developing breast cancer due to reproductive and lifestyle exposures. This evidence concerns the gene PALB2 and breast carcinoma.